Eupraxia Pharmaceuticals
EPRX
54 hedge funds and large institutions have $157M invested in Eupraxia Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 3 closing their positions.
633% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 3
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
54% more funds holding
Funds holding: 35 → 54 (+19)
51% more capital invested
Capital invested by funds: $104M → $157M (+$53.2M)
9.29% more ownership
Funds ownership: 27.31% → 36.59% (+9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$10.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$5.63M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.56M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.22M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$2.09M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$500K |
| 3 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
-$345K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
-$326K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$122K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
BNP Paribas Financial Markets
Paris,
France
| $46.5K | +$51.8K | +6,429 | New |
|
52
JP Morgan Chase
New York
| $3.79K | +$4.61K | +573 | New |
|
53
National Bank of Canada
Montreal,
Quebec, Canada
| $812 | -$1.83K | -227 | -39% |
|
|
CIAM
54
Caitong International Asset Management
Hong Kong
| $7 | +$8 | +1 | New |
|
|
55
Arrowstreet Capital
Boston,
Massachusetts
| – | -$2.09M | -278,064 | Closed |
|
|
QC
56
Quadrature Capital
London,
United Kingdom
| – | -$326K | -43,186 | Closed |
|
|
XT
57
XTX Topco
George Town,
Cayman Islands
| – | -$122K | -16,180 | Closed |
|
EPRX Hedge Fund Activity: Q1 2026 in Review
54 of the 8,137 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q1 2026, worth a combined $157M — up 51% from $104M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new EPRX positions and 3 closed out — a net gain of 19 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $10.4M. The largest seller was Arrowstreet Capital, exiting entirely with an estimated $2.09M sold.
- 54 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q1 2026, up from 35 in Q4 2025.
- Funds reported $157M of Eupraxia Pharmaceuticals stock for Q1 2026, up 51% quarter-over-quarter.
- 22 funds opened new Eupraxia Pharmaceuticals positions in Q1 2026 and 3 closed out, a net change of +19 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q1 2026 was Affinity Asset Advisors, an estimated $10.4M added.
- The largest Eupraxia Pharmaceuticals seller in Q1 2026 was Arrowstreet Capital, an estimated $2.09M sold.
Based on aggregated 13F filings for Q1 2026.